When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Asthma - Wikipedia

   en.wikipedia.org/wiki/Asthma

   Asthma phenotyping and endotyping has emerged as a novel approach to asthma classification inspired by precision medicine which separates the clinical presentations of asthma, or asthma phenotypes, from their underlying causes, or asthma endotypes. The best-supported endotypic distinction is the type 2-high/type 2-low distinction.

3. AOL Mail

   mail.aol.com

   Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!

4. Long-acting beta-adrenoceptor agonist - Wikipedia

   en.wikipedia.org/wiki/Long-acting_beta...

   LABAs are designed to reduce the need for shorter-acting β 2 agonists such as salbutamol (albuterol), as they have an approximately twelve-hour duration of action, compared to about five hours for salbutamol, making them candidates for sparing high doses of corticosteroids [citation needed] or treating nocturnal asthma and providing ...

5. Anti-asthmatic agent - Wikipedia

   en.wikipedia.org/wiki/Anti-asthmatic_agent

   An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...

6. Buteyko method - Wikipedia

   en.wikipedia.org/wiki/Buteyko_method

   The Buteyko method emphasizes the role of carbon dioxide and hyperventilation in respiratory diseases as well as overall health. It is known that hyperventilation can lead to low carbon dioxide levels in the blood (or hypocapnea), which can subsequently lead to disturbances of the acid-base balance in the blood and lower tissue oxygen levels.

7. Medication therapy management - Wikipedia

   en.wikipedia.org/wiki/Medication_therapy_management

   MTM services are provided free to eligible patients enrolled in a plan. As of 2019, to be eligible a patient must have at least two (or three, for some plans) chronic conditions, take multiple drugs covered by Part D, and are predicted to exceed a preset amount in annual out of pocket costs for their covered Part D drugs (set at $3,967 in 2018 ...